Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 4, Issue 135, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3003515
Keywords
-
Categories
Funding
- Foundation for the NIH
- Canadian Institutes for Health Research
- National Health and Medical Research Council (NHMRC)
- Genome Canada
- Michael Smith Foundation for Health Research (MSFHR)
- Canadian Cystic Fibrosis Foundation
- University of Melbourne
Ask authors/readers for more resources
Case fatality rates for severe malaria remain high even in the best clinical settings because antimalarial drugs act against the parasite without alleviating life-threatening inflammation. We assessed the potential for host-directed therapy of severe malaria of a new class of anti-inflammatory drugs, the innate defense regulator (IDR) peptides, based on host defense peptides. The Plasmodium berghei ANKA model of experimental cerebral malaria was adapted to use as a preclinical screen by combining late-stage intervention in established infections with advanced bioinformatic analysis of early transcriptional changes in co-regulated gene sets. Coadministration of IDR-1018 with standard first-line antimalarials increased survival of infected mice while down-regulating key inflammatory networks associated with fatality. Thus, IDR peptides provided host-directed adjunctive therapy for severe disease in combination with antimalarial treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available